Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 5/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.51 |
| ▸ | HTR3B | O95264 | 3/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR5A | P47898 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664800 | 0.84 | HSD11B1 (0.56) | ALDH1A1TSHRHSD11B1 | |
| SCHEMBL3663903 | 0.84 | HSD11B1 (0.46) | ALDH1A1USP2TSHRHSD17B10HTR3A | |
| SCHEMBL8511563 | 0.84 | HSD11B1 (0.65) | ALDH1A1USP2TSHRHSD17B10HTR3A | |
| SCHEMBL3660276 | 0.83 | HSD11B1 (0.47) | ALDH1A1USP2TSHRHSD17B10HSD11B1 | |
| SCHEMBL3666555 | 0.83 | HSD11B1 (0.46) | ALDH1A1USP2TSHRHSD17B10HTR6 | |
| SCHEMBL9982392 | 0.82 | KDM4E (0.52) | ALDH1A1USP2TSHRHSD17B10HSD11B1 | |
| SCHEMBL3657790 | 0.82 | HSD11B1 (0.52) | ALDH1A1USP2TSHRHSD17B10HSD11B1 | |
| SCHEMBL974103 | 0.81 | HDAC1 (0.44) | ALDH1A1USP2TSHRHSD17B10HTR3A | |
| SCHEMBL3660269 | 0.81 | HSD11B1 (0.46) | ALDH1A1USP2TSHRHSD17B10HSD11B1 | |
| SCHEMBL974217 | 0.81 | HSD11B1 (0.44) | ALDH1A1USP2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | claimed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | claimed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | claimed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | claimed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | claimed |
| EP-2238126-B1 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-8530657-B2 | Substituted adamantanes and their therapeutic application | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8211892-B2 | Tetrahydroquinoxaline urea derivatives | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| EP-2238126-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009112691-A2 | DERIVATIVES OF TETRAHYDROQUINOXALINE UREA, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245148-A1 | TETRAHYDROQUINOXALINE UERA DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | UGDH, HNMT, NNMT | ALDH1A1 936/4885USP2 292/4885TSHR 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.